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Abstract
Most antiretroviral therapy (ART) programs in resource-limited settings have historically used non-nucleotide reverse transcriptase
inhibitor (NNRTI)-based regimens with limited access to routine viral load (VL) testing. We examined the long-term success of these
regimens in rural Uganda among participants with 1 measured suppressed VL.
We conducted a prospective cohort study of participants who had been onNNRTI-based first-line regimens for≥4years and had a
VL <1000copies/mL at enrollment in Jinja, Uganda. We collected clinical and behavioral data every 6 months and measured VL
again after 3 years. We quantified factors associated with virologic failure (VF) (VL≥1000copies/mL) using Wilcoxon Rank Sum, chi-
square, and Fisher’s Exact Tests.
We enrolled 503 participants; 75.9% were female, the median age was 45years, and the median duration of time on ART was 6.8
years (IQR=6.0–7.6years). Sixty-nine percent of participants were receiving nevirapine, lamivudine, and zidovudine regimens;
22.5% were receiving efavirenz, lamivudine, and zidovudine; and 8.6% were receiving other regimens. Of the 479 with complete
follow-up data, 12 (2.5%) had VL≥1000copies/mL. VF was inversely associated with reporting never missing pills (41.7% of VFs vs
72.8% non-VFs, P= .034). There were differences in distribution of the previous ART regimens (P= .005), but no clear associations
with specific regimens. There was no association between having a VL of 50 to 999copies/mL at enrollment and later VF (P= .160).
Incidence of VF among individuals receiving ART for nearly 7 years was very low in the subsequent 3 years. NNRTI-based regimens
appear to be very durable among those with good initial adherence.
Abbreviations: 3TC = lamivudine, ART = antiretroviral therapy, AZT = azidothymidine, EFV = efavirenz, HIV = human
immunodeficiency virus, NNRTI = non-nucleotide reverse transcriptase inhibitor, NRTI = nucleotide reverse transcriptase inhibitor,
NVP = neviripine, Q1–Q3 = quartile 1–quartile 3, TAMs = Thymidine Analogue Mutations, TASO = The AIDS Support Organisation,
TDF = tenofovir disoproxil fumurate, VF = virologic failure, VL = viral load, WHO = World Health Organisation.
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failure1. Introduction
At the end of 2018, an estimated 37.9 million people were living
with human immunodeficiency virus (HIV) and 24.5 million had
access to antiretroviral therapy (ART),[1] resulting in substantialEditor: Mehmet Bakir.
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population-level reductions in HIV-associated morbidity, mor-
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(WHO), this approach involves the use of standardized ART
regimens, most often with 2 nucleotide reverse transcriptase
inhibitors (NRTIs) and 1 non-nucleotide reverse transcriptase
inhibitor (NNRTI).[4] Furthermore, initial WHO guidelines did
not recommend the use of viral load (VL) testing for routine
clinical monitoring,[4] given the high cost and lack of evidence
regarding improved clinical outcomes associated with VL
testing.[5–7]
In 2013, WHO issued updated recommendations that VL
testing should be conducted at 6 and 12months after ART
initiation and every 12months thereafter for virologically
suppressed persons.[8] However, expansion of VL testing has
been challenging for many ART programs in sub-Saharan
Africa,[9] and many programs continue to rely on clinical and
immunological monitoring of patients on ART. Furthermore,
NNRTI-based regimens have a lower physiologic barrier to
selecting HIV resistance strains, in comparison to regimens based
on protease-inhibitors.[10] However, HIV care and treatment
programs that have developed effective means to support
participant retention and adherence to therapy have demonstrat-
ed low-levels of virologic failure, even in the absence of VL
monitoring.[11]
We designed a study to determine the durability of NNRTI-
based regimens, in terms of sustained virologic suppression,
among patients who have been receiving ART at a treatment site
in rural Uganda for at least 4 years without previous VL
monitoring.We then examined associations with virologic failure
after an additional 3 years of follow-up.2. Methods
We offered enrollment to clients of The AIDS Support
Organisation (TASO) at the Jinja service centre between June
2012 and April 2013. Participants were aged ≥18years, who had
received ART for at least 4 years and were on first-line ART
regimen which contained an NNRTI-based regimen (nevirapine
or efavirenz). Study procedures were read aloud by a research
assistant in 1 of 2 local languages (Luganda and Lusoga) or
English and all participants provided written informed consent to
participate. Participants continued to receive their regular HIV
care through TASO. The clinic provides comprehensive HIV
care, treatment and prevention services to over 7400 patients and
their families, within a 75-km radius of Jinja town. HIV VL
monitoring was not available for routine clinical care at TASO at
the time of the study. We conducted an HIV VL test at
enrollment. We had a planned enrollment of 500 participants
with a VL of <1000copies/mL, based on the maximum number
of participants we could feasibly follow every 6 months for 3
years while still allowing for a sufficient number of participants
with virologic failure events to analyze. We also enrolled
participants with VL measurements of ≥1000copies/mL but
report on these elsewhere.[12,13] Study participants received an
honorarium of 20,000 Ugandan shillings (approximately $5 US)
to offset travel costs and ameal at each study visit. This study was
approved by the Research Ethics Board of the University of
British Columbia, the Uganda Virus Research Institute and the
Uganda National Council for Science and Technology.
Clinical and behavioral data were collected at enrollment and
every 6months for a period of 3 years, with data collection ending
in September 2016. Collected variables included demographic
information (age, gender, education level, and marital status),2
adherence in terms of self-reported missed doses (never vs once
per week or more vs more than once per week but less than once
per month vs less than once per month), current and past ART
regimens, and ART start dates. CD4 cell counts were measured
every 6months using a FACS Calibur instrument and samples for
additional VLwere drawn every 12months. Plasma samples were
stored in liquid nitrogen and shipped to the Uganda Virus
Research Institute/Medical Research Council (United Kingdom)
in Entebbe for VL testing. Genotypic antiretroviral drug
resistance testing was conducted on samples collected after 36
months of follow-up for all those with a VL>1000copies/mL.
We calculated descriptive statistics of study participant
characteristics. The primary outcome variable of interest was
VL≥1000copies/mL at 36months of follow-up. We conducted
bivariate analyses comparing patients with an endpoint VL<
1000copies/mL vs VL≥1000copies/mL using Fisher’s exact or
chi-square tests for categorical variables and the Wilcoxon rank
sum test for continuous variables. We reported on each variable
individually and missing data were not imputed. As virologic
failure was relatively uncommon, it did not allow us to conduct
multivariable modelling to adjust for confounding. For partic-
ipants with virological failure at 36months of follow-up, we
calculated descriptive statistics (count and percentage) of
Thymidine Analogue Mutations (TAMs), NNRTI mutations,
and K65R mutations. All analyses were conducted using SAS
Version 9.3 (SAS Corporation, Cary, NC).3. Results
We screened 1091 TASO clients who had been receiving first-line
ART for a minimum of 4 years, to identify 113 with VL≥1000
copies/mL, whose outcomes are reported elsewhere.[13] We
enrolled the first 503 participants with VL<1000copies/mL, and
479 (95.2%) completed all study visits up to 36months. Of those
with incomplete data, 15 (3%) had died, 3 (1%) were lost to
follow-up, and 5 (1%) withdrew voluntarily. Of the 479 patients,
364 (75.9%) were female, had a median age of 44years (quartile
1 [Q1]–quartile 3 [Q3]=39–50years), the median duration on
ART at enrollment was 6.8years (Q1–Q3=6.0–7.6years), and
the median baseline CD4 count was 572 (Q1–Q3=451–752
cells/mL). A total of 347 patients (69.0%) were receiving
neviripine with a backbone of azidothymidine and lamivudine
(AZT/3TC/NVP), 113 (22.5%) were receiving efavirenz with the
same backbone (AZT/3TC/EFV), 32 (6.7%) were receiving
neviripine with a backbone of tenofovir disoproxil fumurate and
lamivudine (TDF/3TC/NVP), and 9 (1.8%) were receiving
efavirenz with the same backbone (TDF/3TC/EFV). Of the
503 patients enrolled, 470 (93.4%) had an enrollment VL of<50
copies, 32 (6.4%) had 50 to 500copies/mL, and 1 (0.2%) had
between 500 and 1000copies/mL.
Table 1 shows the results of the bivariate analysis comparing
12 study participants (2.5%) with virologic failure (≥1000
copies/mL) at 36months to the 467 (97.5%) without virologic
failure. Participants who reported no missed pills significantly
were less likely to have virologic failure at study exit (41.7% of
failure patients vs 72.8%% of non-failure patients; P= .0.034).
There were no significant differences in the distribution of ART
regimens at enrollment (P= .071), but there were observed
differences in the distribution of previous regimens participants
had received (P= .005). However, no specific clear association
with a particular previous regimen was apparent. Notably,
previous exposure to regimens containing stavudine (d4T) was
Table 2
Frequency of resistance mutations among those with virologic
failure (n=12).
Resistance mutation n %





NNRTI mutation 11 91.7
K65R 2 16.7
TAMs=Thymidine Analogue Mutations, NNRTI=non-nucleotide reverse transcriptase inhibitor.
Table 1
Bivariable analysis of participant characteristics stratified by virologic failure at 36mo of follow-up.
No virologic failure (n=467) Virologic failure (n=12)
Categorical variables n (row %) n (row %) P
Gender
Female 365 98.1% 7 1.9% .151
Male 102 95.3% 5 4.7%
Marital status
Legally married 128 99.2% 1 0.8% .002
Co-habiting 82 93.2% 6 6.8%
Single/separated/divorced 73 94.8% 4 5.2%
Widowed 184 99.5% 1 0.5%
Education
Less than primary completion 83 96.5% 3 3.5% .688
Completed primary 225 97.8% 5 2.2%
Completed secondary 159 97.5% 4 2.5%
Frequency of missed pills
Never 340 98.6% 5 1.4% .034
Once a month or more 80 95.2% 4 4.8%
Less than once a week but more than once a month 7 87.5% 1 12.5%
Once a week or more 40 95.2% 2 4.8%
ARV regimen at enrollment
Nevirapine/3TC/ZDV 327 97.3% 9 2.7% .071
Efavirenz/3TC/ZDV 102 99.0% 1 1.0%
Nevirapine/3TC/TDF 29 96.7% 1 3.3%
Efavirenz/3TC/TDF 8 100.0% 0 0.0%
Other ARV regimen 1 50.0% 1 50.0%
Previous ARV regimen
Nevirapine/3TC/ZDV 21 95.5% 1 4.5% .005
Efavirenz/3TC/ZDV 10 100.0% 0 0.0%
Nevirapine/3TC/TDF 1 50.0% 1 50.0%
Efavirenz/3TC/TDF 1 100.0% 0 0.0%
Nevirapine/3TC/D4T 205 99.5% 1 0.5%
Efavirenz/3TC/D4T 31 93.9% 2 6.1%
D4T exposure
No 96.3% 9 3.8% 96.3% .141
Yes 98.7% 3 1.3% 98.7%
Viral load at enrollment
<50 440 97.8% 10 .173
50–500 26 92.9% 2
500–1000 1 100.0% 0
Continuous variables Median (IQR) Median (IQR) P
Age (in years) 45 (40–50) 44 (38–50) .509
Duration of ART at enrollment 6.8 (6.0–7.6) 6.4 (5.2–7.5) .397
CD4 cell count at enrollment 577 (462–758) 450 (371–648) .094
CD4 cell count at 36mo 521 (404–700) 394 (176–630) .103
3TC= lamivudine.
Nanfuka et al. Medicine (2021) 100:19 www.md-journal.comnot associated with virologic failure (P= .141). Virologic failure
was more common among individuals who were co-habiting, but
not married (6.8% vs 0.5% of widowed patients; P= .002).
Females were not more likely to have virologic failure at study
exit compared to males (P= .151) and virologic failure was not
significantly different by age (median=45years [Q1–Q3: 40–50]
for non-failure patients vs median=44 [Q1–Q3: 38–50] for
failure patients; P= .509). Also, while CD4 cell count at
enrollment was lower for those with virologic failure at study
exit (median=450cells/mL; Q1–Q3: 371–648] than for those
without failure (median=577; [Q1–Q3: 462–759], these differ-
ence was not statistically significant (P= .094).
Table 2 shows the results distribution of resistance mutations
among those with virologic failure at study exit. Of the 123
Nanfuka et al. Medicine (2021) 100:19 Medicinepatients with VL>1000copies/mL that had resistance data at 36
months, 11 (92%) had at least 1 mutation. All of these had an
NNRTI mutation and 2 (16%) had a K65R mutation. With
respect to TAMs, 10 (83%) had no TAMs, 1 (8%) had 1 TAM,
and 1 (8%) had 3 TAMs.4. Discussion
We observed a very low rate of virologic failure among patients
who had been receiving an NNRTI-based first-line regimen for
over 7 years and had a suppressed VL on their first ever VL test.
Prevalence of virologic failure was 2.4% after an additional 36
months of observation, suggesting that for patients who are
adherent to their ART, NNRTI-based regimens can provide very
durable and effective treatment. These results provide reassur-
ance that NNRTI-based ART can remain viable over the long-
term, and as such, provide further support for current WHO
ART guidelines which recommend efavirenz as an alternative
first-line ART regimen component.[14]
Given the low proportion of participants who developed
virologic failure, we found very few differences between the
failure and non-failure groups. We did, however, find differences
in self-reported adherence to therapy in that 74% of the non-
failure group reporting never missing any pills compared to only
40% in the failure group. This is interesting considering that all
participants must have been sufficiently adherent to their therapy
to achieve virologic suppression prior their first study visit and
reinforces the need to re-visit supports for adherence to therapy
even in individuals who have been receiving ART for long periods
of time. We did find some differences in the distribution of
previous ART regimens, but both failures and non-failures
occurred across most of the regimens available. While we also
found statistically significant differences in the distribution of
marital status among those with virologic failure and those
without, the absolute differences in terms of percentages were
quite small. Individuals who were co-habiting but not legally
married had the highest proportion of virologic failure (6.8%).
However, given that 93% of co-habiting participants achieved
virologic suppression, it would be hard to state definitely that co-
habitation is a risk factor for subsequent virolgic failure.
Another notable finding is the relatively few number of drug
resistance mutations we found among those who developed
treatment failure. Most of those with failure had only 1 drug
resistance mutation (largely NNRTI mutations) and 10 of the 12
participants with virologic had no TAMs, the mutations which
are of most concern in terms of their effects on second-line
therapy. These are in stark contrast to the patients who we found
to have virologic failure during enrollment,[12] where we found
that 83% had 2 or more mutations and 45% had ≥2 TAMs.
An important negative finding was that we did not find that
low-level viremia at enrollment (between 50 and 999copies/mL)
predicted virologic failure at study exit. This observation has
been shown previously in high-income countries[15] and lends
support to the principle that low-level viremia is of limited clinical
consequence, provided that adequate adherence to therapy can be
maintained. It also further supports the continued use of a VL>
1000copies/mL as the WHO definition for virologic failure.[16]
An ongoing challenge with the use of NNRT-based regimens
will be the steady increase in primary drug resistance to these
medications. According to the WHO 2017 HIV Drug Resistance
Report, the prevalence of pre-treatment NNRTI resistance ranges
from8% inCameroon to 15% inUganda[17] and the prevalence of4
pre-treatment drug resistance to NNRTIs was below 5% in South
Africa until 2011, but increased to10.0%by2014.[18]Whether the
increased availability of VL testing will help to mitigate these
increases remains to be seen, given that the ability to provide pre-
treatment drug resistance testing is very limited in the region.[17]
This study has a number of limitations. Firstly, we had very few
participants who developed virologic failure, which limited our
ability to detect factors associated with failure. Secondly, we had
only 2 viral load result points at enrollment and 36months of
follow-up therefore because of this, we could not ascertain at
what exact time of follow-up virologic failure occurred.
However, overall retention this cohort was excellent with over
95% completing all follow-up visits and very low rates of
mortality and loss-to-follow-up. It is also notable that the
virologic suppression overall in this program was excellent,
estimated to be 93% in among unselected patients receiving
treatment for more than 4 years,[11] even in the absence of prior
VL testing. Clearly the ART programs implemented by TASO
have effectively engaged their patients in long-term ART care.
Lastly, adherence to therapy among participants was, by
necessity very good or excellent prior to enrollment as they
would have been unlikely to have achieved virologic suppression
after 7 years on these regimens without excellence adherence. As
such we have very limited ability to examine how lower levels of
adherence in subsequent years may have altered these outcomes.
In summary, we found a very low incidence of virologic failure
among patients who had been receiving NNRTI-based first-line
ART for a median of 7 years at enrollment. This demonstrates
that individuals who achieve virologic success while on NNRTIs
can expect them to remain effective for very long periods of time,
even without routine VL testing as long as they remain adherent.
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